Pharming Group (NASDAQ:PHAR - Get Free Report) shares saw strong trading volume on Wednesday . 5,941 shares traded hands during mid-day trading, a decline of 5% from the previous session's volume of 6,240 shares.The stock last traded at $11.68 and had previously closed at $11.95.
Analysts Set New Price Targets
Several analysts have recently issued reports on the company. Oppenheimer increased their target price on Pharming Group from $30.00 to $39.00 and gave the stock an "outperform" rating in a report on Friday, March 14th. HC Wainwright reissued a "buy" rating and issued a $37.00 target price on shares of Pharming Group in a report on Thursday, March 20th.
Check Out Our Latest Stock Report on PHAR
Pharming Group Price Performance
The company has a debt-to-equity ratio of 0.41, a quick ratio of 2.76 and a current ratio of 3.53. The company has a market cap of $813.99 million, a price-to-earnings ratio of -46.02 and a beta of 0.02. The business has a fifty day moving average price of $9.49 and a 200 day moving average price of $9.10.
Pharming Group (NASDAQ:PHAR - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.22) earnings per share for the quarter, beating analysts' consensus estimates of ($0.25) by $0.03. The company had revenue of $79.09 million for the quarter, compared to the consensus estimate of $67.74 million. Pharming Group had a negative net margin of 6.09% and a negative return on equity of 7.65%. As a group, research analysts anticipate that Pharming Group will post -0.2 earnings per share for the current year.
Pharming Group Company Profile
(
Get Free Report)
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.
See Also
Before you consider Pharming Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pharming Group wasn't on the list.
While Pharming Group currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
